A phase i study of docetaxel, oxaliplatin, & capecitabine (DOC) As first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction

Cancer Investigation

Volumn 28, Issue 8, 2010, Pages 833-838

  Malik, Imtiaz ^a   Bernal, Pedro ^a   Byrd, Janet ^b  

^a Loma Linda Oncology Medical Group Inc   (United States)

^b LOMA LINDA UNIVERSITY HEALTH   (United States)

Author keywords

Chemotherapy; clinical trial; esophageal cancer; stomach cancer

Indexed keywords

CAPECITABINE; DOCETAXEL; OXALIPLATIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DOSE CALCULATION; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG DOSE ESCALATION; FATIGUE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CHEMICALLY INDUCED; DRUG ADMINISTRATION; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS; TOXICITY;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FATIGUE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TAXOIDS; VOMITING;

EID: 77956634440     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003630942     Document Type: Article

References (37)

1. Alexander, H.R.; Kelsen, D.P.; Tepper, J.E. Cancer of the stomach. In Cancer: Principles and Practice of Oncology, V.T. DeVita, S. Hellman, S.A. Rosenberg (eds). Philadelphia, PA: Lppincott-Raven, 1997, 1021-1054.
2. Ajani, J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005, 10(Suppl. 3), 574-587.
3. Cen, P.; Ajani, J.A. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol 2007, 23, 631-635.
4. Ohtsu, A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008, 43, 256-264.
5. Catalano, V.; Labianca, R.; Beretta, G.D.; Gatta, G.; de Brand, F.; Van Custem, E. Gastric cancer. Crit Rev Oncol Hematol 2009, 71, 127-164.
6. Liu, G.; Franssen, E.; Fitch, M.I., Warner, E. Patients preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15, 110-115.
7. Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 1998, 34, 1274-1281.
8. Ishikawa, T.; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka, H. Tumor selective delivery of 5-FU by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Bichem Pharmacol 1998, 55, 1091-1097.
9. Schüller, J.; Cassidy, J.; Dumont, E.; Roos, B.; Durston, S.; Banken, L.; Utoh, M.; Mori, K.; Weidekamm, E.; Reigner, B. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45, 291-297.
10. Takebayashi, Y.; Akiyama, S.; Akiba, S.; Yamada, K.; Miyadera, K.; Sumizawa, T.; Yamada, Y.; Murata, F.; Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996, 88, 1110-1117.
11. Ishikawa, T.; Sekiguchi, F.; Fukase, Y.; Sawada, N.; Ishitsuka, H. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58, 685-690.
12. Koizumi, W.; Saigenji, K.; Ujiie, S.; Terashima, M.; Sakata, Y.; Taguchi, T.; Clinical Study Group of Capecitabine. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003, 64, 232-236. (Pubitemid 36438808)
13. Ajani, J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006, 107, 221-231.
14. Dhillon, S.; Scott, L.J. Capecitabine: in advanced gastric and oesophagogastric cancer. Drugs 2007, 67, 601-610.
15. Sulkes, A.; Smyth, J.; Sessa, C.; Dirix, LY.; Vermorken, J.B.; Kaye, S.; Wanders, J.; Franklin, H.; LeBail, N.; Verweij, J. Taxotere in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994, 70, 380-383.
16. Einzig, A.; Neuberg, D.; Remick, S.C.; Karp, D.D.; ODwyer, P.J.; Stewart, J.A.; Benson, A.B. 3rd. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996, 13, 87-93.
17. Graziono, F.; Catalano, V.; Baldelli, A.M.; Giordani, P.; Testa, E.; Lai, V.; Catalano, G.; Battelli, N.; Cascinu, S. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000, 11, 1263-1266.
18. Ajani, J.A. Docetaxel for gastric and esophageal carcinomas. Oncology 2002, 16, S89-S105.
19. Deeks, E.D.; Scott, L.J. Docetaxel: in gastric cancer. Drugs 2007, 67, 1893-1901.
20. Hainsworth, J.D. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004, 9, 538-545.
21. Rivera, E.; Meijia, J.A.; Arun, B.K.; Adinin, R.B.; Walters, R.S.; Brewster, A.; Broglio, K.R.; Yin, G.; Esmaeli, B.; Hortobagyi, G.N.; Valero, V. Phase 3 study comparing the use of docetaxel on an every 3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008, 112, 1455-1461.
22. Roth, A.D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M.S.; Pagani, O.; Morant, R.; Borner, M.M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch A. Taxotereplatinol( TC): an effective drug combination in gastric cancer. Ann Oncol 2000, 11, 301-306.
23. Giordano, K.F.; Jatoi, A.; Stella, P.J.; Foster, N.; Tschetter, L.K.; Alberts, S.R.; Dakhil, S.R.; Mailliard, J.A.; Flynn, P.J.; Nikcevich, D.A. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006, 17, 652-656.
24. Raymond, E.; Faivre, S.; Woynarowski, J.M.; Chaney, S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25, 4-12.
25. Louvet, C.; Andre, T.; Tigaud, J.M.; Gamelin, E.; Douillard, J.Y.; Brunet, R.; Francois, E.; Jacob, J.H.; Levoir, D.; Taamma, A.; Rougier, P.; Cvitkovic, E.; de Gramont, A. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002, 20, 4543-4548.
26. Borner, M.; Dietrich, D.; Stupp, R.; Morant, R.; Honegger, H.; Wernli, M.; Herrmann, R.; Pestalozzi, B.C.; Saletti, P.; Hanselmann, S.; Müller, S.; Brauchli, P.; Castiglione-Gertsch, M.; Goldhirsch, A.; Roth, A.D. Phase II study of capecitabine and oxaliplatin in firstand second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002, 20, 1759-1766.
27. Kim, D.Y.; Kim, J.H.; Lee, S.H.; Kim, T.Y.; Heo, D.S.; Bang, Y.J.; Kim, N.K. Phase II study of oxaliplatin, 5-fluorouracail and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003, 14, 383-387.
28. Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A.R.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358, 36-46.
29. Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997, 8, 876-885.
30. Sawada, N.; Ishikawa, T.; Fukase, Y.; Nishida, M.; Yoshikubo, T.; Ishitsuka, H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xerografts. Clin Cancer Res 1998, 4, 1013-1019.
31. Yamamoto, S.; Kurebayashi, J.; Kurosumi, M.; Kunisue, H.; Otsuki, T.; Tanaka, K.; Sonoo, H. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xerografts. Cancer Chemother Pharmacol 2001, 48, 283-288.
32. Wagner, A.D.; Grothe, W.; Haerting, J.; Kleber, G.; Grothey, A.; Fleig, W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24, 2903-2909.
33. Van Custem, E.; Moiseyenko, V.M.; Tjulandin, S.; Majlis, A.; Constenla, M.; Boni, C.; Rodrigues, A.; Fodor, M.; Chao, Y.; Voznyi, E.; Risse, M.L.; Ajani, J.A. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24, 4991-4997.
34. Ajani, J.A.; Moiseyenko, V.M.; Tjulandin, S.; Majlis, A.; Constenla, M.; Boni, C.; Rodrigues, A.; Fodor, M.; Chao, Y.; Voznyi, E.; Awad, L.; Van Cutsem, E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric and gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007, 25, 3210-3216. (Pubitemid 47325603)
35. Ilson, D.H. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007, 25, 3188-3190.
36. Roth, A.D.; Fazio, N.; Stupp, R.; Falk, S.; Bernhard, J.; Saletti, P.; Köberle, D.; Borner, M.M.; Rufibach, K.; Maibach, R.; Wernli, M.; Leslie, M.; Glynne-Jones, R.; Widmer, L.; Seymour, M.; de Braud, F. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubucin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007, 25, 3217-3223.
37. Evans, D.; Miner, T.; Akerman, P.; Millis, R.; Jean, M.; Kennedy, T.; Safran, H. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 2007, 30, 346-349.